Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California. TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferrara to...
ONEOK Announces Board of Directors Additions Mark A. McCollum and Precious Williams Owodunni Join ONEOK Board of Directors TULSA, Okla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- The board of directors of ONEOK, Inc. (NYSE: OKE) elected Mark A. McCollum and Precious Williams Owodunni as independent directors to the board, effective January 23, 2026. McCollum, 66, is the retired president and chief executive officer of Weatherford International plc, having led the company from April 2017 through June 2020. Before joining Weatherford, he served as executive vice president and chief financial...
ONEOK Increases Quarterly Dividend 4% TULSA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The board of directors of ONEOK, Inc. (NYSE: OKE) today increased its quarterly dividend to $1.07 per share, an increase of 4%. This increase results in an annualized dividend of $4.28 per share. The dividend is payable Feb. 13, 2026, to shareholders of record at the close of business Feb. 2, 2026.----------------------------------------------------------------------------------------------------------------At ONEOK (NYSE: OKE), we deliver energy products and services vital to an advancing world. We are a l...
ONEOK Schedules Fourth-quarter and Year-end 2025 Conference Call and Webcast TULSA, Okla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- ONEOK, Inc. (NYSE: OKE) will release fourth-quarter and year-end 2025 earnings after the market closes on Feb. 23, 2026. Members of ONEOK’s management team will participate in a conference call the following day. What: ONEOK fourth-quarter and year-end 2025 earnings conference call and webcast When: 11 a.m. Eastern, Feb. 24, 2026 10 a.m. Central Where: 1) Phone conference call dial 800-225-9448, conference ID: OKE4Q25 2) Log on to the webcast at If you are una...
Occidental to Announce Fourth Quarter Results Wednesday, February 18, 2026; Hold Conference Call Thursday, February 19, 2026 HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) will announce its fourth quarter 2025 financial results after close of market on Wednesday, February 18, 2026, and will hold a conference call to discuss the results on Thursday, February 19, 2026, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international callers dial 1-412-317-5417) or via webcast at . Participants may pre-register for the conference call ...
Occidental Completes Sale of OxyChem HOUSTON, Jan. 02, 2026 (GLOBE NEWSWIRE) -- (NYSE: OXY) announced today it has completed the sale of its chemical business, OxyChem, to Berkshire Hathaway (NYSE: BRK.A, BRK.B) for $9.7 billion in cash, subject to customary purchase price adjustments. “This transaction accelerates our strategy to strengthen Occidental’s balance sheet and focus on our deep and diverse oil and gas portfolio which we have transformed over the last decade. We expect to operate our high-return oil and gas assets to deliver long-term value while driving innovation across our...
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deducting placement age...
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety ...
ONEOK to Participate in Investor Conference TULSA, Okla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- ONEOK, Inc. (NYSE: OKE) will participate in an investor conference this week and in a fireside chat session at 2:15 p.m. Eastern Time (1:15 p.m. Central Time) on Tuesday, Dec. 9. The session will be webcast live on ONEOK’s website at . The webcast will also be available for replay. ONEOK’s latest investor materials are available at . ------------------------------------------------------------------------------------------------------------------- At ONEOK (NYSE: OKE), we deliver energy produ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.